B.S., Chemical Engineering, University of California, Los Angeles, CA; 1995
Ph.D., Bioengineering, UW, Seattle, WA; 2004
M.D., Medical Scientist Training Program, UW School of Medicine; 2006
Internal Medicine Residency: University of California, San Francisco, CA; 2006-2009
Fellowship: UW, Hematology/Oncology Fellowship Program, Seattle, WA; 2009-2012
Research Associate, Clinical Research Division, FHCRC; 2013-2015
Dr. Orozco’s clinical expertise is in hematologic malignancies, including leukemias and lymphomas, and he works to tailor treatment plans to deliver high quality care. He is actively involved in translational research, in the laboratory and the clinic, investigating novel therapeutic approaches that more precisely target cancers and that are thereby less toxic, improving therapeutic options for patients.
Dr. Orozco’s primary research focus is developing “radioimmunotherapies” that use immune system proteins known as antibodies to selectively target radioactivity to cancer cells, sparing normal tissues. The antibody, and its radioactive payload, locates and kills tumor cells by damaging their DNA. Dr. Orozco’s research employs preclinical cancer models and involves radiographic imaging techniques, antibody characterization and therapeutic engineering, as well as analyses of immune system function and cellular damage repair mechanisms.
Improving outcomes after blood stem cell transplantation with alpha radioimmunotherapy
In ongoing studies, Dr. Orozco is working to identify the ideal alpha radionuclide to be used in radioimmunotherapies that can reduce relapse risks after transplantation, including transplants in which haploidentical (half-matched) family members serve as donors. Using a murine leukemia model, he is testing 90Y, 211At and 131I bound antibodies that recognize a molecule called CD45 that is found on most blood cells, including leukemia cells. He is working to identify optimal chemotherapy combinations and radiation doses as well as the ideal radionuclide that produce the best stem cell engraftment and survival with the lowest toxicities.
Dr. Orozco is currently the Principal Investigator on two clinical trials.
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome Study Number: 2186.00; Phase: II.
Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patient; Study Number: 2572.00; Phase: I/II.